1-Year Controlled Randomised Trial of Prevention of Early Postmenopausal Bone Loss by Intranasal Calcitonin

Reginster, Jean Yves; Albert, Adelin; Lecart, Marie-Paule; Lambelin, P; Denis, Danielle; Deroisy, Rita; Fontaine, M.; Franchimont, P

doi:10.1016/s0140-6736(87)92619-5

Cited by 191 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regnister JY et al who conducted study on 79 women who had been menopausal for less than 36 months intranasal salmon calcitonin 50 IU/day for 5 days per week reported an increase in BMD by 1.38. 13 This was comparable with our study. Intravenous Zolindronic acid has improved the mean T score of lumbar spine by 1.91 over one year.…”

Section: Discussionsupporting

confidence: 92%

A comparative evaluation of intanasal salmon calcitonin and intravenous zolondrinic acid in the treatment of postmenopausal osteoporosis

Santosha

2017

Int J Res Orthop

View full text Add to dashboard Cite

Background: Osteoporosis is a progressive disorder of the bones which is characterized by reduction in bone mass and increased risk of fractures. Various drugs are available for the treatment of osteoporosis and prevention of osteoporotic fractures. Zolindronic acid and salmon calcitonin are the first line of therapy among these. The aim of the study was to compare the effectiveness intanasal salmon calcitonin and intravenous zolondrinic acid the treatment of postmenopausal osteoporosis Methods: The study was conducted in the Department of Orthopaedics at a tertiary care centre from January 2015 to Jan 2017. One group received treatment with intravenous zolindronic acid 5mg administered as a single dose. Other group received a salmon calcitonin which was administered intranasally 100IU/day. Results were compared. Results: Total 80 patients were included in the study. Forty patients were allotted to each group. Mean T score of BMD of the patients in the salmon calcitonin group before the start of study was -3.38 and mean T score of the patients in the zolindronic acid group was -3.4. Which improved to -1.9 and -1.49 for the calcitonin group and zolindronic acid treated group respectively. Conclusions: Once yearly intravenous zolindronic acid is superior to intranasal salmon calcitonin in the treatment of post-menopausal osteoporosis.

show abstract

Section: Discussionsupporting

confidence: 92%

A comparative evaluation of intanasal salmon calcitonin and intravenous zolondrinic acid in the treatment of postmenopausal osteoporosis

Santosha

2017

Int J Res Orthop

View full text Add to dashboard Cite

show abstract

“…The physiological role of calcitonin in the maintenance of bone mass is suggested by studies showing that conditions associated with osteoporosis such as age (7) and female sex (8,9) show lower serum calcitonin levels than observed in young individuals and in males. Furthermore, calcitonin administration increases bone mineral density (BMD) in postmenopausal women (10,11). In contrast, several studies have shown that acquired calcitonin deficiency or excess has no effect on bone mass or mineral metabolism in adults (12) and the only long-lasting randomized study of calcitonin treatment showed that the effect of calcitonin on bone mass gain was less than expected (13).…”

Section: Introductionmentioning

confidence: 99%

Impact of congenital calcitonin deficiency due to dysgenetic hypothyroidism on bone mineral density

Daripa

Paula

Rufino

et al. 2004

Braz J Med Biol Res

View full text Add to dashboard Cite

The objective of the present study was to determine the effect of chronic calcitonin deficiency on bone mass development. The results of 11 patients with thyroid dysgenesis (TD) were compared to those of 17 normal individuals (C) and of 9 patients with other forms of hypothyroidism (OH): 4 with hypothyroidism due to inborn errors of thyroid hormone synthesis and 5 with Hashimoto's thyroiditis. The subjects received an intravenous calcium stimulus and blood was collected for the determination of ionized calcium (Ca 2+ ), calcitonin, and intact parathyroid hormone. Bone mineral density (BMD) was determined by dual-energy X-ray absorptiometry. After calcium administration the levels of Ca 2+ in the two groups of hypothyroidism were significantly higher than in the normal control group (10 min after starting calcium infusion: C = 1.29 ± 0.08 vs TD = 1.34 ± 0.03 vs OH = 1.34 ± 0.02 mmol/l; P < 0.05), and only the TD group showed no calcitonin response (5 min after starting calcium infusion: C = 27.9 ± 5.8 vs TD = 6.6 ± 0.3 vs OH = 43.0 ± 13.4 ng/l). BMD values did not differ significantly between groups (L2-L4: C = 1.116 ± 0.02 vs TD = 1.109 ± 0.03 vs OH = 1.050 ± 0.04 g/cm 2 ). These results indicate that early deficiency of calcitonin secretion has no detrimental effect on bone mass development. Furthermore, the increased calcitonin secretion observed in patients with inborn errors of thyroid hormone biosynthesis does not confer any advantage in terms of BMD.

show abstract

“…Calcitonin has been reported to be effective in the treatment of postmenopausal osteoporosis in both short-term, noncontrolled (4-6) and long-term, placebo-controlled studies (7)(8)(9). However, Jowsey et al (10) failed to obtain any beneficial effects with this drug when compared with calcium supplementation alone in 26 women with osteoporosis, and Wallach et al ( 11) obtained an increase in total body calcium in only half of treated patients.…”

Section: Introductionmentioning

confidence: 99%

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Civitelli¹,

Gonnelli²,

Zacchei³

et al. 1988

J. Clin. Invest.

344

100

View full text Add to dashboard Cite

To investigate the effectiveness of calcitonin treatment of postmenopausal osteoporosis in relation to bone turnover, we examined 53 postmenopausal osteoporotic women before and after one year of therapy with salmon calcitonin (sCTJ), at the dose of 50 IU every other day. Baseline evaluation revealed that 17 (32%) patients had high turnover (HTOP), and 36 (68%) normal turnover osteoporosis (NTOP) as assessed by measurement of whole body retention (WBR) of 9"'Tc-methylene diphosphonate. The two groups did not differ in terms of bone mineral content (BMC) measured by dual photon absorptiometry at both lumbar spine and femoral diaphysis. However, HTOP patients had higher levels of serum osteocalcin (OC) and urinary hydroxyproline excretion (HOP/Cr). Multivariate regression analysis showed no correlation between parameters of bone turnover (WBR, OC, HOP/Cr) and both femoral and vertebral bone density; the latter being negatively correlated only with the years elapsed since menopause (R2 = 0.406). Treatment with sCI' resulted in a significant increase of vertebral BMC in the 53 patients taken as a whole group (±7%, P < 0.001). When the results obtained in HTOP and NTOP were analyzed separately, only those with HTOP showed a marked increment of spinal BMC (+22%, P < 0.001), NTOP subjects neither gained nor lost bone mineral during the study. Femoral BMC decreased in the whole group after sCT therapy (-3%, P < 0.003). However, HTOP patients maintained initial BMC values, whereas those with NTOP lost a significant amount of bone during the study period (-5%, P < 0.001). The increase of vertebral bone mass was associated with a marked depression of bone turnover detectable in both subsets of patients and in the whole group. In conclusion: (a) assessment of bone turnover cannot help predict the severity of bone loss in postmenopausal osteoporosis; (b) calcitonin therapy appears to be particularly indicated for patients with high-turnover osteoporosis, resulting in a net gain of bone mineral in the axial skeleton and a slowing of bone loss in the appendicular bones.

show abstract

1-Year Controlled Randomised Trial of Prevention of Early Postmenopausal Bone Loss by Intranasal Calcitonin

Cited by 191 publications

References 17 publications

A comparative evaluation of intanasal salmon calcitonin and intravenous zolondrinic acid in the treatment of postmenopausal osteoporosis

A comparative evaluation of intanasal salmon calcitonin and intravenous zolondrinic acid in the treatment of postmenopausal osteoporosis

Impact of congenital calcitonin deficiency due to dysgenetic hypothyroidism on bone mineral density

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Contact Info

Product

Resources

About